Introduction

Cancer remains one of the most severe global public health challenges. Traditional mainstream cancer treatments including radiotherapy, chemotherapy and targeted therapy often face a common bottleneck: treatment resistance. Once cancer cells develop tolerance to conventional therapies, patients will suffer from disease progression and poor survival outcomes. To break this dilemma, research teams from multiple affiliated hospitals of Guangxi Medical University have launched in-depth explorations on three prevalent malignant tumors—nasopharyngeal carcinoma, glioma and EGFR-mutant non-small cell lung cancer. A series of innovative therapeutic schemes have been verified through preclinical experiments and multicenter clinical trials, with relevant research findings published in top international academic journals. These studies provide feasible new treatment directions for patients with drug-resistant cancers worldwide. This article systematically sorts out these latest research breakthroughs and interprets core professional medical terms for global readers.

1. Engineered Exosome Delivery System Helps Reverse Radiation Resistance in Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma is a highly prevalent malignant tumor in South China and Southeast Asia. Radiotherapy serves as the first-line treatment for this disease, yet nearly 30% of patients eventually develop radiation resistance, which directly leads to treatment failure.

A research group from the First Affiliated Hospital of Guangxi Medical University clarified a key pathogenesis of radiotherapy resistance in nasopharyngeal carcinoma. The overexpression of the SP1 protein can induce the abnormal proliferation of tumor blood vessels. These deformed blood vessels build a protective barrier for cancer cells, greatly weakening the killing effect of radiation on tumor tissues.

To break this protective shield, the research team developed an engineered exosome delivery system. As a kind of biological nanoparticle carrier, engineered exosomes can accurately transport inhibitory drugs to abnormal tumor blood vessels without damaging normal human tissues. After repairing the structure of tumor blood vessels, radiotherapy can regain its expected anti-tumor efficacy. Compared with traditional systemic chemotherapy, this targeted delivery method effectively reduces adverse side effects on healthy organs and tissues, bringing new treatment hopes to patients with recurrent and radiation-resistant nasopharyngeal carcinoma.

2. Intermittent Fasting: An Economical Adjuvant Treatment for Glioma

Glioma is an aggressive intracranial malignant tumor with limited available treatment options. Conventional surgery combined with chemoradiotherapy often brings heavy economic burdens and severe physical side effects to patients. Therefore, exploring low-cost and safe auxiliary treatment methods has long been a research hotspot in neuro-oncology.

A research team from the Institute of Life Sciences of Guangxi Medical University has published relevant research results in a sub-journal of Nature. The study confirmed that intermittent fasting exerts subtype-specific anti-tumor effects on Tp53 mutant glioma. By regulating the composition of intestinal flora and methionine metabolism in the human body, intermittent fasting changes the level of N⁶-methyladenosine (m⁶A) RNA methylation, further inhibits the overactivation of the TGF-β tumor-promoting signaling pathway, and significantly slows the proliferation and invasion of glioma cells.

This research provides reliable experimental evidence for non-drug adjuvant anti-cancer therapy. As an easy-to-implement intervention method, intermittent fasting can be combined with standard clinical treatment regimens to improve the prognosis of glioma patients while controlling medical costs.

3. Targeted Combined Chemotherapy Optimizes Survival Outcomes of EGFR-Mutant Lung Cancer Patients

EGFR mutation is the most common gene variation in non-small cell lung cancer. For patients with concurrent tumor suppressor gene co-mutations, single targeted therapy often fails to achieve long-term disease control.

Researchers from the Affiliated Cancer Hospital of Guangxi Medical University participated in a global multicenter clinical trial, whose research paper was published in CA: A Cancer Journal for Clinicians, the highest-impact journal in the field of oncology. The trial data proved that compared with single targeted drugs, the combined regimen of targeted therapy and chemotherapy can significantly prolong progression-free survival and overall survival for this group of lung cancer patients.

This research revises the previous single-drug treatment strategy for EGFR-mutant lung cancer with complex gene variations and forms a standardized precision treatment reference scheme for clinical oncologists around the world.

Glossary of Core Medical Terms

1. Engineered Exosome Delivery System: Manually modified tiny biological carriers that can accurately transport anti-tumor drugs to lesion sites to achieve targeted treatment and reduce systemic side effects.
2. Radiation Resistance: A biological state in which tumor cells adapt to radiation damage, resulting in significantly reduced radiotherapy efficacy.
3. Intermittent Fasting: A nutritional intervention strategy with periodic food restriction, applied as an auxiliary anti-tumor treatment in this study.
4. N⁶-methyladenosine (m⁶A): The most common epigenetic modification on messenger RNA, which can regulate tumor cell proliferation, metastasis and drug resistance.
5. Immune Checkpoint Inhibitor: A type of anti-cancer drug that reactivates the body’s own immune system to recognize and attack cancer cells.
6. Targeted Combination Chemotherapy: A treatment mode combining targeted drugs acting on specific cancer gene sites and traditional chemotherapeutic drugs to overcome tumor drug resistance.
7. Transarterial Chemoembolization (TACE): A minimally invasive local treatment for malignant tumors, which cuts off the blood supply of tumors and locally releases anti-cancer drugs to kill cancer cells.

Conclusion

The three cancer research achievements from Guangxi Medical University focus on the most tricky clinical pain point—treatment resistance. From precise nanoparticle drug delivery and low-cost nutritional auxiliary intervention to optimized combined medication schemes, these studies enrich the global arsenal of anti-cancer therapies from multiple dimensions of precision medicine, translational medicine and clinical treatment.

Medical science is a global collaborative cause. All the above research results are based on international academic communication and cross-regional data cooperation. The research team expects to carry out deeper joint research, clinical trial cooperation and academic exchanges with medical institutions, biopharmaceutical enterprises and scientific research institutions from all over the world. Through open scientific cooperation, these innovative anti-cancer strategies can be continuously optimized, accelerated to clinical transformation, and bring survival benefits to cancer patients in every region of the world.